As CBO at Lexent Bio, Ted is leveraging his hybrid experience in oncotherapeutics and molecular diagnostics to launch the Confera™ DX system for therapy response monitoring. He has deep experience in both sectors, having built and led the original commercial team at Genomic Health that created and launched the Oncotype® DX product line in 2004. Before that, he led oncology marketing teams at Amgen and ALZA. He later built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, where he launched the Vectra® DA system for disease management in rheumatology. Returning to therapeutics, he was Oncology/Hematology Business Unit Head at Jazz Pharma. He then served as CBO at Counsyl, an innovative NGS lab in reproductive genetics. More recently he was CCO at Guardant Health. Ted is in a very small group that has successfully commercialized separate RNA, DNA & Proteomic tools for specialty medicine, unlocking widespread clinical adoption.
Liquid Biopsy Showcase:
Lexent Bio is building and commercializing novel liquid biopsy applications to change the way we manage cancer, with an initial focus on accelerating the feedback for assessing the effectiveness of therapy.
Better, Faster Molecular Response Assessment for Oncology
The Confera™ DX system will allow clinicians to know how patients are responding to treatment, faster and more accurately than currently possible. Launching as an LDT and transitioning to IVD, Confera DX will enable performance-based pricing for expensive cancer therapies.
The PMWC 2020 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).